Dec. 6 Company Quick Takes: Alexion rebuffs activist’s push for sale; plus UCB, Genmab, Enzyvant, Biohaven

Under activist pressure, Alexion decides against proactive sale process
Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) rose 6% Friday, boosting the company’s market cap by $1.4 billion, after the company said in a statement that its board has decided not

Read the full 380 word article

User Sign In